Welcome to the

8TH Annual Meeting of ISMPP!

Collaborations in the

Medical Publications Arena

Session Moderator: Julia Ralston

President, MedErgy HealthGroup

Past President, ISMPP (2010-2011)

Why are collaborations important?

1. Building alliances helps to maximize success

within an individual company

2. Sharing best practices ensures that we work

in a united fashion to help inform internal and

external stakeholders

3. Collaborations help break down silos and

improve communications

4. All of the above

Session Objectives

• Become familiar with the organizational

collaborations that exist in the medical

publishing space

• Know how some of the ongoing collaborations

across various groups within our profession

may impact us

Session Speakers

• Jodie Gillon, Leighton Chipperfield, and Martin

Delahunty

– Case study on collaborations: One company’s

alliances with the publishing world

• Greg Thompson

– ISMPP I&A Committee update

• Mary-Margaret Lannon

– An update from MPIP

• Liz Wager

– An update from COPE

Welcome to the

8TH Annual Meeting of ISMPP!

Practical Solutions

for a

Complex Medical Publications World

Case Study on Collaborations:

One Company’s Alliances with

the Publishing World

Leighton Chipperfield, Publishing Director Elsevier

Martin Delahunty, Associate Director Nature Publishing Group

Jodie Gillon, Director Publications Management Team, Pfizer

Pfizer’s External Collaborations Efforts

• Internal team (3 members) formalized in 2011

• Main goals:

– Increase awareness among stakeholders of our

policies to support transparency

– Strengthen our relationship with publishers/editors

– Coordinate with Internal Awareness Campaign

2012 Goal

• Improve acceptance rates for manuscript submission

to peer-reviewed journals to improve the timeliness of

publication more efficient utilization of resources. Use

experience and influencing skills to guide appropriate,

realistic target journal selection by internal and

external authors

• Target

– Meets: more than 50% accepted at 1st choice journal and

more than 75% accepted at 1st or 2nd choice journal

– Exceeds: more than 65% accepted at 1st choice journal and

more than 75% accepted at 1st or 2nd choice journal

Past Collaborations

• MPIP; COPE

• Lunch and learns at Publisher & Pfizer:

– Nature

– Elsevier

– Wiley Blackwell

– Springer

– Adis

– Biomed central

– JTE/Post graduate medicine

– Thompson Reuters

What was shared?

• Pfizer's structure, policies and procedures –

beyond publically accessible information

• Publishers updates

– New journals

– Offerings/policies

– Social media/enhanced articles

• Hot topics

– Authorship

– Review papers

What we learned that was

surprising

Trends in biomedical research funding

driving publications

Other

2%

NIH

27%

Drug &

medical device

companies

58%

Other US federal

4%

Charities/foundations

4%

State/local government

5%

Measurements of ‘Reach’ are changing…

20 years ago, ‘reach’ = print circulation

Today: reach is increasingly about article downloads , with different types of access models coming on-stream

Tomorrow: smartphones, social media, apps and the semantic web provide new opportunities to measure reach

Social media provides opportunities for immediate awareness and usage

>42k ‘likes’ >24k followers

Multimedia enhancements

Some journals are offering additional ways to promote published content, such as:

• Author generated ‘video abstracts’

• KOL roundtable video discussing an article http://supplements.amjmed.com/2010/incretin-based-

therapies-type-2-diabetes/

• Online resource centers focussed on a disease area, sponsored by educational grant

Content Dissemination

• NPG press service is subscribed to by more than 2,000 journalists and

media organisations worldwide.

• Content can be highlighted on one of the Nature Facebook pages or by one

of our popular Twitter accounts, such as Nature Medicine or Nature News.

Pharma Solutions Helps Identify Clinical Trial

Studies for Publication

1. Meetings with Pfizer: Meet with publication planning

team to identify papers for submission and review

benefits of publishing high-quality clinical trial papers

2. Poster Sessions at Conferences: Attend various

professional meetings to review abstracts of industry-

sponsored studies for possible journal submission.

3. Clinicaltrials.gov: Identify Phase II and Phase III trials

in clinicaltrials.gov and contact Lead Investigator or

Industry sponsor about submitting manuscripts based on

those trials.

4. Lead Investigator Outreach: Solicit papers from Lead

Investigators who conduct the most clinical trials in

various therapeutic areas as indicated in PubMed.

Workflow Submission to Publication

Pre-submission

enquiry

Fast track review

options available

for some journals

Fast track paper

receives decision

within

guaranteed time

Pharma Solutions

provides journal

metrics

Print publication in

next available issue

Advance Online

Publication

Before submission Peer review Publication

Online author proofs

avoid unnecessary

delays during the

revision process

Please refer to individual journal

instructions to authors

Pharma Solutions can provide

review times for individual journals

Online version fully searchable

and citable via DOI

Pre-submission Inquiries

Peer Review

• Rapid Review for time-pressured papers Some journals offer expedited review for an additional charge

Typically under 2 weeks from acceptance to first decision

Check time to publication if accepted

• Journal ‘cascades’ Arrangement to pass a paper rejected from journal A to journal B for consideration,

with author approval

Can be useful where journal B is a good second choice

Saves significant time reformatting and re-submitting

Take into account all pros and cons

Publication Ethics and Compliance

• Constantly working to ensure our journals are compliant with the latest

best practice guidelines

• Instructions to authors vary by journal and society but cover areas such

as policies on authorship, trial registration, IRB approval, proper

EQUATOR reporting guidelines and checklists, etc.

• Member and/or supportive of the work of many associations including:

– International Committee of Medical Journal Editors (ICMJE)

– Medical Publishing Insights and Practices Initiative (MPIP)

– Good Publication Practice (GPP2)

– Committee on Publication Ethics (COPE)

What surprised the publishers / editors

• Depth of knowledge on content, journal processes and

quality metrics (eg. Impact Factor)

• Marketing firewalls

• Rigorous internal policies and procedures:

– Authorship

– Disclosure

– supplements

• Size and scale of group (13 across all products)

• Openness in sharing info – beyond publically available

• Approach to publications planning:

– Prioritizing concerns

– Manage expectations

What we changed because of this

engagement?

Publishers Pfizer

Value of clinical trials: outreach Policy on review papers

Formalized pre-submission inquiry

process

Pre-submission inquiries = routine

Revised guide/instructions to

authors

Expanded journal selection

Optimization of peer-review Increased awareness/promotion of

open access

Improve timing: fast track Improved journal mapping

Negative results Piloted social media

Benefits of Collaborations

To the publishers To Pfizer

Opportunity to learn of our processes Opportunity to learn of new

journals/journals outside our norm

Can better support our needs Learn of changes in publishers/editors

policies

Can adapt their processes to suit our

legal/regulatory constraints

Influence changes to better suit

pharma’s needs

Discuss how readers consume

information/implications for both

Discuss hot topics: authorship, review

papers

Happy to learn of roles and

responsibilities

Learn about digital/social media/open-

access: What are other companies

doing?

Nothing beats face to face! Build relationships: Pre-submission

inquiries/cascading/guidance

Welcome to the

8TH Annual Meeting of ISMPP!

Practical Solutions

for a

Complex Medical Publications World